Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab plus hypofractionated stereotactic radiotherapy for 1–4 brain metastases in NSCLC
2018-004490-27Phase 2Completed
- Sponsor
- Institut Claudius Regaud
- Start
- Jun 2019
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of durvalumab in non-small cell lung cancer (NSCLC) and brain metastases (2 arms), sponsored by Institut Claudius Regaud. Primary endpoint: Time to intracranial progression. Started Jun 2019; status: completed.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)brain metastases
Beyond the preview
Go deeper on 2018-004490-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004490-27.